drugset / Trial / NCT04837235
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. There were 3 dose cohorts (75mg, 90mg, 105mg) with 12 healthy subjects in each cohorts (6 males and 6 females). This study includes an 11-day Screening Period, a 1-day single dose and 7-days multiple doses Treatment Period.
Timeline
- Start
- 2021-04-29
- Primary completion
- 2021-08-01
- Completion
- 2021-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUFEMILAST | Small molecule | 75 mg | Oral |
| Subject | MUFEMILAST | Small molecule | 90 mg | Oral |
| Subject | MUFEMILAST | Small molecule | 105 mg | Oral |